Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s10557-016-6711-0

http://scihub22266oqcxt.onion/10.1007/s10557-016-6711-0
suck pdf from google scholar
C5346598!5346598 !28185035
unlimited free pdf from europmc28185035
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28185035 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28185035 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid28185035
      Cardiovasc+Drugs+Ther 2017 ; 31 (1 ): 63-75
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Anthracycline Chemotherapy and Cardiotoxicity #MMPMID28185035
  • McGowan JV ; Chung R ; Maulik A ; Piotrowska I ; Walker JM ; Yellon DM
  • Cardiovasc Drugs Ther 2017[Feb]; 31 (1 ): 63-75 PMID28185035 show ga
  • Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon. Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient.
  • |Animals [MESH]
  • |Anthracyclines/*adverse effects [MESH]
  • |Antibiotics, Antineoplastic/*therapeutic use [MESH]
  • |Cardiotoxicity [MESH]
  • |Cardiovascular Agents/therapeutic use [MESH]
  • |Cytoprotection [MESH]
  • |Heart Diseases/*chemically induced/metabolism/physiopathology/prevention & control [MESH]
  • |Humans [MESH]
  • |Myocytes, Cardiac/*drug effects/metabolism/pathology [MESH]
  • |Risk Factors [MESH]
  • |Signal Transduction/drug effects [MESH]
  • |Time Factors [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box